New drug combo aims to stop liver Cancer's return
NCT ID NCT06467799
Summary
This study is testing a new treatment plan to stop liver cancer from coming back after surgery. Patients with high-risk liver cancer will receive a combination of targeted chemotherapy and an immunotherapy drug before their operation, followed by more immunotherapy after surgery. The main goal is to see if this approach can keep the cancer from returning within the first year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.